Get the app
US › Healthcare

Alcon AG (ALC)

US · Healthcare · Medical Instruments & Supplies

$66.18-0.60%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$2.82B
Revenue YoY
+8.7%
Net profit
$0
Profit YoY
-100.0%
EPS
$0.84
EPS estimate
$0.77
Net margin
0.0%

EPS came in at 0.84 against a street estimate of 0.77 — a beat of 9.1%.

Key statistics

Market cap
$31.99B
P/E
50.1
Forward P/E
16.2
P/B
1.46
Book value
$44.67
EPS (TTM)
$1.32
Dividend yield
0.54%
52-week high
$87.22
52-week low
$61.84
50-day MA
$68.47
200-day MA
$72.48
Beta
0.73

Analyst view

Analysts rate Alcon AG a buy (21 buy, 5 hold, 1 sell out of 27) with an average price target of $82.73.

Shareholding

Insiders
0.20%
Institutions
63.35%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.05%
Bank of New York Mellon Corp2.70%
NORGES BANK2.27%
Amvescap Plc.2.15%
Ako Capital Llp2.00%
Aristotle Capital Management LLC1.89%
Zurcher Kantonalbank1.64%
FMR Inc1.59%

Recent filings & reports

DocumentDate
Quarterly results (6-K) · Q2 2026
HEADLINE NUMBERS • Second-quarter 2026 net sales rose 8% to $2,782 million; first-half sales rose 9% to $5,467 million. • Second-quarter gross profi
2026-08-10
Quarterly results (6-K) · Q1 2026
HEADLINE NUMBERS • First-quarter 2026 net sales rose 10% to $2,685 million from $2,451 million, including favorable currency impacts. • Gross profit
2026-05-05
Current report (6-K) · Q2 2026
HEADLINE NUMBERS • Alcon’s 2025 net income was CHF 62,753 thousand. • Earnings available to the Annual General Meeting were CHF 17,870,449 thousand,
2026-04-02
Annual report FY2025 (20-F)
HEADLINE NUMBERS • Alcon filed its Form 20-F for the fiscal year ended December 31, 2025. • The company has 487,427,920 outstanding ordinary shares.
2026-02-24
Current report (6-K) · Q4 2025
HEADLINE NUMBERS • 2025 net sales rose 5% as reported, or 4% on a constant-currency basis, to $10.3 billion. • Diluted EPS was $1.98; core diluted
2026-02-24
Quarterly results (6-K) · Q4 2025
HEADLINE NUMBERS • 2025 net sales increased 5% to $10,319 million from $9,836 million. Fourth-quarter sales increased 9% to $2,702 million from $2,47
2026-02-24
Current report (6-K) · Q1 2026
OTHER NOTABLE POINTS • Alcon Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission on January 6, 2026. • The filing references a pr
2026-01-07
Quarterly results (6-K) · Q3 2025
HEADLINE NUMBERS • Third-quarter 2025 net sales rose 6% to $2,589 million; nine-month sales rose 4% to $7,617 million. • Third-quarter operating inc
2025-11-12

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$0.36 / share
ex-date May 6, 2026 · pay May 7, 2026
2026-05-06

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alcon AG — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.